STOCK TITAN

LeMaitre Vascular (LMAT) Stock News, May-Nov 2022

LMAT NASDAQ

LeMaitre Vascular, Inc. provides devices, implants, and services for the treatment of peripheral vascular disease. The company develops, manufactures, and markets disposable and implantable vascular devices for vascular surgeons, with products used in arteries and veins.

Recurring LMAT news includes quarterly financial results, guidance, dividend declarations, and management presentations at healthcare investor conferences. Company updates also discuss product categories such as Artegraft, grafts, valvulotomes, and carotid shunts, along with sales activity across the Americas, EMEA, and Asia Pacific.

Rhea-AI Summary

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its participation in two significant investor conferences. David Roberts, President, will present at the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 3:10 PM ET in New York City. Additionally, he will present at the Sidoti Small-Cap Virtual Conference on December 8, 2022, at 1:15 PM ET. LeMaitre specializes in devices for treating peripheral vascular disease, impacting over 200 million individuals globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
conferences
-
Rhea-AI Summary

LeMaitre Vascular, Inc. (Nasdaq:LMAT) will participate in two investor conferences. David Roberts, President, will present at the Stifel Healthcare Conference on November 15, 2022, at 3:00 PM ET in New York City. Additionally, CFO JJ Pellegrino will host 1x1 meetings at the Canaccord Genuity Forum on November 17, 2022, also in New York City.

LeMaitre specializes in devices for treating peripheral vascular disease, impacting over 200 million people globally. More details are available at www.lemaitre.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
conferences
-
News
Rhea-AI Summary

LeMaitre (Nasdaq:LMAT) reported Q3 2022 results with sales of $39.0 million, a 2% increase year-over-year. Operating income fell 32% to $6.2 million with a margin of 16%. Net income decreased 16% to $5.5 million, with earnings per share at $0.25, down 17%. Sales growth was driven by carotid shunts (+23%) and other products. The company also announced a quarterly dividend of $0.125 per share, payable December 1, 2022. Guidance for Q4 2022 estimates sales of $39.8-$42.2 million and expects a gross margin of 65.8%. Cash and investments rose by $4.1 million to $79.7 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.09%
Tags
Rhea-AI Summary

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced it will release its third quarter 2022 financial results on October 27, 2022, after market close. A conference call is scheduled for 5:00 PM ET that same day to discuss the results, business highlights, and outlook. LeMaitre specializes in devices for peripheral vascular disease, which affects over 200 million people globally. The company manufactures and markets disposable and implantable vascular devices tailored for vascular surgeons.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
-
Rhea-AI Summary

BURLINGTON, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced that President David Roberts will engage in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference. This event is scheduled for September 14, 2022, at 4:40 PM ET, taking place at the Sheraton New York Hotel.

LeMaitre Vascular specializes in devices and services for peripheral vascular disease, impacting over 200 million globally, offering solutions tailored for vascular surgeons.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
conferences
-
Rhea-AI Summary

LeMaitre Vascular (Nasdaq:LMAT) announced that CFO JJ Pellegrino will present at the Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022, at 12:00 PM ET in Boston. The company focuses on devices, implants, and services for treating peripheral vascular disease, affecting over 200 million people globally. LeMaitre develops and markets vascular devices aimed at the needs of vascular surgeons. For more details, visit lemaitre.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
conferences
News
Rhea-AI Summary

LeMaitre (LMAT) reported Q2 2022 sales of $42.1 million, up 4% year-over-year. Gross margin increased to 66.0%. However, operating income fell 48% to $5.8 million, and EPS declined by 60% to $0.16. The company announced a quarterly dividend of $0.125/share and increased guidance for 2022 to 10% organic growth. Key growth drivers included biologics, especially XenoSure (+21%).

The company closed its St. Etienne factory, incurring a $3.1 million special charge.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
-
Rhea-AI Summary

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced it will release its Q2 2022 financial results on July 28, 2022, after market close. The company has scheduled a conference call at 5:00 PM ET the same day to discuss the results, business highlights, and future outlook. LeMaitre specializes in developing and marketing devices and services for treating peripheral vascular disease, which impacts over 200 million people globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
-
Rhea-AI Summary

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced that its President, David Roberts, will present at the Sidoti Summer Small Cap Virtual Conference on June 15, 2022, at 2:30 PM ET. The company specializes in devices and services for treating peripheral vascular disease, which affects over 200 million individuals globally. LeMaitre develops and markets both disposable and implantable vascular devices tailored for vascular surgeons. For additional information, visit www.lemaitre.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
conferences
Rhea-AI Summary

LeMaitre Vascular, Inc. (Nasdaq:LMAT) will participate in two investor conferences in May and June 2022. CFO JJ Pellegrino is set to present at the UBS Global Healthcare Conference on May 23 at 2:00 PM ET in New York City. Additionally, President David Roberts will present at the Jefferies Healthcare Conference on June 8 at 9:30 AM ET, also in New York City. LeMaitre is a key provider of devices and services for treating peripheral vascular disease, affecting over 200 million people globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.43%
Tags
conferences

FAQ

What is the current stock price of LeMaitre Vascular (LMAT)?

LeMaitre Vascular (LMAT) last closed at $74.86.

What is the market cap of LeMaitre Vascular (LMAT)?

The market cap of LeMaitre Vascular (LMAT) is approximately $1.7B.